Literature DB >> 23205078

Characterization of PAR1 and FGFR1 expression in invasive breast carcinomas: Prognostic significance.

Marta Tiburcio1, Sandra M A Costa, Maria DE Fatima Duarte, Fernando C Schmitt, Adhemar Longatto Filho.   

Abstract

Breast cancer is the most common cause of cancer mortality among women worldwide. Among the several factors associated with breast cancer development, angiogenesis plays an essential role and has currently emerged as a potential diagnostic, prognostic and therapeutic target. Protease-activated receptor 1 (PAR1) and fibroblast growth factor receptor 1 (FGFR1) have important activities in tumor angiogenesis and progression. The aim of this study was to investigate the prognostic significance of these two receptors, hypothesising significant correlations between receptor expression in tumor angiogenesis and clinicopathological parameters customarily used in breast cancer prognosis and prediction. Formalin-fixed and paraffin-embedded samples of ductal invasive breast carcinomas were used to analyze the expression of PAR1 and FGFR1, in the tumor cells as well as in the tumor stroma, and further determine intratumoral microvessel density (iMVD) to quantify intratumoral angiogenesis. Correlations between PAR1 and FGFR1 expression in tumor cells and stroma, iMVD and several clinicopathological parameters and molecular markers used in breast cancer diagnosis have been addressed. The correlation between PAR1 and FGFR1 suggests an association of the two receptors with a more aggressive breast cancer phenotype and, consequently, a potential role during tumor progression. The results reported in the present study also emphasize the importance of microenvironmental factors in tumor progression, while precluding the positive association between iMVD and breast cancer aggressiveness.

Entities:  

Year:  2012        PMID: 23205078      PMCID: PMC3506650          DOI: 10.3892/ol.2012.806

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  33 in total

1.  A signaling pathway leading to metastasis is controlled by N-cadherin and the FGF receptor.

Authors:  Kimita Suyama; Irina Shapiro; Mitchell Guttman; Rachel B Hazan
Journal:  Cancer Cell       Date:  2002-10       Impact factor: 31.743

2.  P-cadherin expression is associated with high-grade ductal carcinoma in situ of the breast.

Authors:  Joana Paredes; Fernanda Milanezi; Leda Viegas; Isabel Amendoeira; Fernando Schmitt
Journal:  Virchows Arch       Date:  2002-01       Impact factor: 4.064

3.  Conditional activation of FGFR1 in the prostate epithelium induces angiogenesis with concomitant differential regulation of Ang-1 and Ang-2.

Authors:  S F Winter; V D Acevedo; R D Gangula; K W Freeman; D M Spencer; N M Greenberg
Journal:  Oncogene       Date:  2007-02-12       Impact factor: 9.867

4.  PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells.

Authors:  Adrienne Boire; Lidija Covic; Anika Agarwal; Suzanne Jacques; Sheida Sherifi; Athan Kuliopulos
Journal:  Cell       Date:  2005-02-11       Impact factor: 41.582

Review 5.  Fibroblast growth factors in development and cancer: insights from the mammary and prostate glands.

Authors:  Kathryn L Schwertfeger
Journal:  Curr Drug Targets       Date:  2009-07       Impact factor: 3.465

6.  Blockade of PAR1 signaling with cell-penetrating pepducins inhibits Akt survival pathways in breast cancer cells and suppresses tumor survival and metastasis.

Authors:  Eric Yang; Adrienne Boire; Anika Agarwal; Nga Nguyen; Katie O'Callaghan; Powen Tu; Athan Kuliopulos; Lidija Covic
Journal:  Cancer Res       Date:  2009-07-21       Impact factor: 12.701

7.  Vessel density assessed by endoglin expression in breast carcinomas with different expression profiles.

Authors:  Nair Lopes; Bárbara Sousa; Daniella Vieira; Fernanda Milanezi; Fernando Schmitt
Journal:  Histopathology       Date:  2009-11       Impact factor: 5.087

Review 8.  Hallmarks of cancer: the next generation.

Authors:  Douglas Hanahan; Robert A Weinberg
Journal:  Cell       Date:  2011-03-04       Impact factor: 41.582

9.  FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas.

Authors:  Jorge Sergio Reis-Filho; Pete T Simpson; Nicholas C Turner; Maryou Ballo Lambros; Chris Jones; Alan Mackay; Anita Grigoriadis; David Sarrio; Kay Savage; Tim Dexter; Marjan Iravani; Kerry Fenwick; Barbara Weber; David Hardisson; Fernando Carlos Schmitt; Jose Palacios; Sunil R Lakhani; Alan Ashworth
Journal:  Clin Cancer Res       Date:  2006-11-15       Impact factor: 12.531

10.  FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis.

Authors:  Somaia Elbauomy Elsheikh; Andrew R Green; Maryou B K Lambros; Nicholas C Turner; Matthew J Grainge; Des Powe; Ian O Ellis; Jorge S Reis-Filho
Journal:  Breast Cancer Res       Date:  2007       Impact factor: 6.466

View more
  4 in total

1.  Serum Dickkopf-1 expression level positively correlates with a poor prognosis in breast cancer.

Authors:  Shao-jie Zhou; Shou-rong Zhuo; Xiao-qing Yang; Chun-xin Qin; Zi-liang Wang
Journal:  Diagn Pathol       Date:  2014-08-13       Impact factor: 2.644

2.  MiR-361-5p inhibits glycolytic metabolism, proliferation and invasion of breast cancer by targeting FGFR1 and MMP-1.

Authors:  Fei Ma; Lei Zhang; Li Ma; Yiyun Zhang; Jianguo Zhang; Baoliang Guo
Journal:  J Exp Clin Cancer Res       Date:  2017-11-13

Review 3.  Fibroblast growth factor family as a potential target in the treatment of hepatocellular carcinoma.

Authors:  Stacey J Coleman; Richard P Grose; Hemant M Kocher
Journal:  J Hepatocell Carcinoma       Date:  2014-05-29

4.  Syndecan-1 Promotes Angiogenesis in Triple-Negative Breast Cancer through the Prognostically Relevant Tissue Factor Pathway and Additional Angiogenic Routes.

Authors:  Eyyad Nassar; Nourhan Hassan; Eslam A El-Ghonaimy; Hebatallah Hassan; Mahmoud Salah Abdullah; Theresa V Rottke; Ludwig Kiesel; Burkhard Greve; Sherif Abdelaziz Ibrahim; Martin Götte
Journal:  Cancers (Basel)       Date:  2021-05-12       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.